FDA Issues Technical Specifications for CGM Data Submission in Clinical Trials Supporting NDA/BLA Applications

Regulatory teams preparing marketing applications that incorporate continuous glucose monitoring endpoints now have a formal technical reference point: FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have jointly issued guidance specifying how CGM data must be submitted in clinical trials supporting an NDA or BLA.

The guidance, filed under docket FDA-2017-D-6821, establishes technical specifications for CGM dataset formatting and submission. Although FDA guidance documents do not carry legally enforceable weight under 21 CFR 10.115, alignment with these specifications during study design and data collection reduces the likelihood of deficiency letters during review, a material consideration for teams managing submission timelines.

For clinical operations and biostatistics leads, the practical read is straightforward: CGM data collected outside these specifications may require reformatting or supplemental submission, adding review cycles that compress launch windows. Early protocol-level alignment with the technical requirements is the lower-risk path, particularly for programs where glucose control is a primary or secondary endpoint.

Regulatory affairs leads should also note that the guidance applies across both drug and biological product applications, meaning development teams working on insulin analogs, GLP-1 receptor agonists, or other metabolic agents face the same submission architecture regardless of the reviewing division.

Comments on the guidance may be submitted at any time via FDA's online docket portal or by mail to Dockets Management, FDA, 5630 Fishers Lane, Rm 1061, Rockville, MD 20852, referencing docket number FDA-2017-D-6821.

The extent to which sponsors have already integrated CGM-specific data standards into their clinical data management systems will likely become a visible checkpoint during pre-NDA/BLA meetings with CDER and CBER review divisions.

Source: FDA Center for Drug Evaluation and Research / Center for Biologics Evaluation and Research via FDA Guidance Documents portal, May 7, 2026. Docket: FDA-2017-D-6821.